Research Article

Interleukin-22 Might Act as a Double-Edged Sword in Type 2 Diabetes and Coronary Artery Disease

Figure 4

IL-22 protected HUVECs from LPC-induced injury in a concentration-dependent manner. Cells were treated with LPC (10 μg/mL) for 12 h, followed by incubation with different concentrations of IL-22 for 24 h. The apoptotic rate was quantified by flow cytometry. Cell viability was analyzed using the CCK-8 assay and the results were compared with those obtained for the control group. Data shown represent mean ± SEM of three independent experiments. versus control group; ; versus LPC-treated group.
(a)
(b)
(c)